Healthcare Providers

Healthcare Providers

Physician Fact Sheet

Trial Title

CRDF-004 trial is a Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation.
Brief Summary of CRDF-004
The purpose of this study is to assess 2 different doses of onvansertib, an orally bioavailable highly selective PLK1 inhibitor with a 24 hour half-life, to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (mCRC) in the first-line setting. This is a randomized trial with a control arm of FOLFOX+BEV or FOLFIRI+BEV. The CRDF-004 study provides an opportunity for newly diagnosed patients with RAS mutated mCRC to obtain onvansertib in combination with standard of care treatment.

Learning more about the CRDF-004 trial

For more information about Cardiff Oncology’s ongoing clinical trial in metastatic colorectal cancer, CRDF-004, you can: